Congress Materials

Medical Information
Afrique
 

This medical information website is intended only for healthcare professionals in Africa. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

I am a healthcare professional registered to practice in AfricaYes, I am a healthcare professional
SelectI am a healthcare professional registered to practice in AfricaYes, I am a healthcare professional
I am not a Healthcare ProfessionalNo, go back to the patient portal
SelectI am not a Healthcare ProfessionalNo, go back to the patient portal
Where do you work / live?
SubmitSubmit
I am a Healthcare Professional in another country.

Congress Materials

The information on this page pertains to selected congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.

Poster
Patel K, Sano D, Maris M, Lesokhin A, von Keudell G, Doucette K, Ramachandren R, Pavlov D,  Uger R, Molloy N, Bruns I, Scheuber A, Iyer S June 4, 2022 ASCO 2022 Hematology

TTI-622-01: A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients with Advanced Hematologic Malignancies, Including Diffuse Large B Cell Lymphoma (DLBCL)

View Presentation
Poster
Patel K, Orlowski RZ, Doucette K, Maris M, Pianko M, Ramachandren R, Stevens D, Vesole D, Uger R, Scheuber A, Molloy N, Bruns I, Lesokhin A June 4, 2022 ASCO 2022 Hematology

TTI-622-01: A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients with Advanced Hematologic Malignancies, Including Multiple Myeloma

View Presentation
Oral Presentation
Lesokhin AM, Arnulf B, Nievizky R, Mohty M, Bahlis NJ, Tomasson MH, Rodrίguez-Otero P, Quach H, Raje NS, Iida S, Raab M-S, Czibere A, Sullivan S, Leip E, Viqueira A, Leleu X June 5, 2022 ASCO 2022 Hematology

Initial Safety Results for MagnetisMM-3: A Phase 2 Trial of Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

View Presentation View Abstract Plain Language Summary
Poster
Laetsch TW, Janeway KA, Hawkins DS, Juszczak-Kosela K, Muscal JA, Collier AB June 5, 2022 ASCO 2022 Other/Multi-Tumor

Randomized Phase 2 Study to Evaluate Palbociclib (IBRANCE®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Ewing Sarcoma 

View Presentation View Abstract Plain Language Summary
Poster
Chawla SP, Kelly CM, Gordon EM, Quon DV, Moradkhani A, Chua VS, Thompson TM, Scheuber A, Bruns I, Allgood VE, Movva S June 5, 2022 ASCO 2022 Other/Multi-Tumor

TTI-621-03: A Phase 1/2 Study of TTI-621 in Combination with Doxorubicin in Patients with Unresectable or Metastatic High-Grade Leiomyosarcoma (LMS) 

View Presentation
Poster
Yeh C, Zhou M, Bapodra N, Rivero M, Espinal-Dominguez E, Moran M, Hershman DL, Fojo T, Bates SE June 6, 2022 ASCO 2022 Breast Cancer

A Novel Analysis of Data From the PALOMA-3 Trial Confirms the Efficacy of Palbociclib and Provides an Option for Efficacy Assessments that Could Accelerate Drug Approvals

View Presentation View Abstract Plain Language Summary
Poster
Pascual J, Martin M,   Proszek P,   Gil-Gil M,   Reay A,   Zielinski C,   Herranz J, Cutts R, Ruiz-Borrego M, Feber A, Ciruelos EM, Swift C, Munoz M, Bermejo B, Margeli M, Li Y, García-Murillas I,   Hubank M, Turner NC June 6, 2022 ASCO 2022 Breast Cancer

Baseline and Longitudinal ctDNA Biomarkers in GEICAM/2013-02 (PEARL) Trial Cohort 2 Comparing Palbociclib and Fulvestrant (PAL + FUL) versus Capecitabine (CAPE)

View Presentation
Poster
Szmulewitz RZ, Holzbeierlein J, Azad AA, Iguchi T, Villers A, Alcaraz A, Alekseev B, Shore ND, Rosbrook B, Zohren F, Ma J, Haas GP, Gomez-Veiga F, Stenzl A, Armstrong AJ June 6, 2022 ASCO 2022 Prostate Cancer

Clinical Outcomes and Safety of Enzalutamide (ENZA) Plus Androgen Deprivation Therapy (ADT) in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis

View Presentation View Abstract Plain Language Summary
Poster
Saad F, George DJ, Cookson MS, Saltzstein DR, Tutrone R, Garnick MB, Brown B, Lu S, Fallick M, Hanson S, Crawford ED, Shore ND June 6, 2022 ASCO 2022 Prostate Cancer

Efficacy and Safety of Relugolix in Men with Advanced Prostate Cancer Based on Baseline Body Mass Index (BMI): A Subgroup Analysis From the Randomized, Phase 3 HERO Study versus Leuprolide

View Presentation View Abstract Plain Language Summary
Poster
Bearz A, Martini J-F, Jassem J, Kim S-W, Chang G-C,  Shaw AT, Shepard D, Dall'O' E, Polli A, Thurm H, Zalcman G, Garcia Campelo MR, Penkov K, Hayashi H, Solomon BJ June 6, 2022 ASCO 2022 Lung Cancer

Phase 3 Trial of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC): Comprehensive Plasma and Tumor Genomic Analyses

View Presentation View Abstract Plain Language Summary